Taxotere is Listed on the Pharmaceutical Benefits Scheme

Our brothers in Australia can finally have access to Taxotere! The Pharmaceutical Benefits Scheme (PBS) has finally listed Taxotere for men with hormone refractory prostate cancer. Now, our brothers in Australia will not have to personally pay to obtain their Taxotere. Up until this point, those who were able to afford to pay for Taxotere [...]

Kwirks and Problems with the FDA’s Approval Process

Often, the FDA limits access to clinical trials to patients who have failed all other approved therapies. This means that we only evaluate potential new drugs on individuals who are already very sick and have been weakened by their disease as well as their prior treatments. Cancer cells "learn" how to survive treatments by mutating. [...]

Go to Top